Get the Stockscreener App
5.8028
0.81%
-0.0472
Redhill Biopharma Ltd Adr stock is traded at $5.8028, with a volume of 6,465.
It is down -0.81% in the last 24 hours and down -11.81% over the past month.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
See More
Previous Close:
$5.85
Open:
$5.815
24h Volume:
6,465
Relative Volume:
0.42
Market Cap:
$7.60M
Revenue:
$35.75M
Net Income/Loss:
$11.57M
P/E Ratio:
-1.5243
EPS:
-3.8069
Net Cash Flow:
$-26.25M
1W Performance:
-1.80%
1M Performance:
-11.81%
6M Performance:
-58.40%
1Y Performance:
-57.31%
1-Day Range:
$5.60
$5.8646
1-Week Range:
$5.60
$6.26
52-Week Range:
$5.41
$20.28
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
Compare RDHL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
5.61 | 7.60M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
ZTS
Zoetis Inc
|
171.47 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.54 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.5455 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.70 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
122.92 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-11-20 | Initiated | BTIG Research | Buy |
| Jul-12-19 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-12-19 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Jan-26-18 | Initiated | Nomura | Buy |
| Oct-06-17 | Initiated | Seaport Global Securities | Buy |
| Oct-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-17 | Reiterated | FBR & Co. | Outperform |
| Jul-27-16 | Reiterated | FBR Capital | Outperform |
| Sep-29-15 | Initiated | Nomura | Buy |
| Jul-29-15 | Reiterated | ROTH Capital | Buy |
| Jun-17-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-15 | Reiterated | ROTH Capital | Buy |
View All
Redhill Biopharma Ltd Adr Stock (RDHL) Latest News
Earnings call transcript: RedHill Biopharma Q1 2022 sees revenue dip - Investing.com
RedHill tests opaganib with Bayer's drug in prostate cancer study By Investing.com - Investing.com South Africa
RedHill tests opaganib with Bayer's drug in prostate cancer study - Investing.com
RedHill stock rises on expanded Medicare coverage - Investing.com
RedHill stock rises on expanded Medicare coverage By Investing.com - Investing.com South Africa
GAMMA Investing LLC Buys 595 Shares of ArcelorMittal S.A. (NYSE:MT) - Defense World
RedHill wins $8 million judgment in New York court - Investing.com India
RedHill Biopharma: FDA Accepts TALICIA’s NDA - Investing.com
COVID-19 Competitive Landscape 2024 (Updated) - openPR
BARDA funds RedHill's opaganib for Ebola treatment - Investing.com
Medi-Cal extends Talicia access for 15 million Californians - Investing.com
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines - StockTitan
Can Redhill Biopharma Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
RDHL stock’s current quarter earnings estimates: What analysts predict? - US Post News
Talicia® Launched in the United Arab Emirates - StockTitan
Taking on analysts’ expectations and winning: Redhill Biopharma Ltd. ADR (RDHL) - SETE News
Redhill Biopharma stock hits 52-week high of $8.03 amid volatility - Investing.com
Opaganib shows promise in obesity, diabetes treatment - Investing.com India
Balance Sheet Breakdown: Redhill Biopharma Ltd. ADR (RDHL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Redhill Biopharma Ltd. ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
RedHill Biopharma Announces Positive Obesity and Diabetes Results with Opaganib - Investing.com
Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo Finance
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
Its Stock Has Paid Off Big Time For Teck Resources Ltd - SETE News
Are Smart Investors Making the Right Decision? Redhill Biopharma Ltd. ADR (RDHL) - SETE News
Check Out Aveanna Healthcare Holdings Inc (AVAH)’s Trade Data Rather Than the Analysts’ Views - SETE News
RDHL’s Stock Tango: The Dance of Gains and Losses in 2023 - The InvestChronicle
Can you now get a good deal on Redhill Biopharma Ltd. ADR’s shares? - US Post News
RedHill Biopharma finalizes agreement to enhance cash position - Investing.com
RedHill secures new US patent for H. pylori treatment Talicia - Investing.com
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042 - PR Newswire
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR
symbol__ Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034 - PR Newswire
LLY Stock Quote Price and Forecast - CNN
Phil and RedHill Biopharma Partner to Increase Access to Talicia® - Business Wire
Peptic Ulcer Drugs Market Drivers Analysis | CAGR of 3.5% - Market.us
Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet - Yahoo Finance
RedHill’s Aemcolo® Granted FDA QIDP 5-Year Exclusivity Extension - BioSpace
RedHill presents New Talicia® and Movantik® data analyses at ACG 2022 - EurekAlert
Cathie Wood Predictions 2022 - New Trader U
RedHill presents new Talicia® data analyses at DDW 2022 - EurekAlert
RedHill Biopharma Stock: Looking At An Unexciting Dead-End (NASDAQ:RDHL) - Seeking Alpha
RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI - BioSpace
RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204 - BioSpace
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib - Yahoo Finance
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement - Yahoo Finance
RedHill Biopharma to Focus Commercial Efforts on Talicia® - GlobeNewswire
Is Senseonics Holdings, Inc. (SENS) Going to Burn These Hedge Funds? - Yahoo Finance
RedHill Biopharma: TALICIA Launch For H. Pylori In Sight - Investing.com
Redhill Biopharma Ltd Adr Stock (RDHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
3.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):